Longboard Pharmaceuticals

Regeneron shares fell 10% due to Eylea sales uncertainty; UCB found bright spots in Alzheimer's drug study; Madrigal's Rezdiffra sales exceeded expectations; AbbVie partnered with EvolveImmune for cancer drugs; another company withdrew a Longboard acquisition offer; FDA to re-evaluate PTC Therapeutics' Translarna for Duchenne muscular dystrophy.

DelveInsight's 'Epilepsy Pipeline Insight, 2024' report details 75+ companies developing 90+ therapies, including RLS103, CT-010, EQU 001, and others, with insights on mechanism of action, route of administration, and clinical trials. Key companies include Novartis, Pfizer, Sanofi, and Takeda, among others.

Lundbeck to acquire Longboard Pharmaceuticals for $2.6 billion, gaining bexicaserin, an investigational treatment for seizures in Dravet syndrome and other DEEs. Bexicaserin, an oral therapy targeting 5-HT2C receptors, showed significant seizure reduction in Phase 1b/2a trials and maintained efficacy in a one-year extension study. The acquisition aims to address critical unmet needs in severe epilepsies.

Bright Minds Biosciences' stock surged over 1,500% due to Lundbeck's $2.6 billion acquisition of Longboard Pharmaceuticals, whose lead asset, bexicaserin, targets 5-HT2C receptors. Bright Minds' BMB-101, also a 5-HT2C agonist for DEEs, initiated its Phase 2 study last month, positioning it similarly to Longboard.

Not all 85 Longboard Pharmaceuticals employees will be part of Lundbeck’s plans to create double-digit billion-dollar revenues from Longboard’s most promising drug.

Lundbeck to acquire Longboard Pharmaceuticals for $2.6 billion, gaining epilepsy drug bexicaserin. The deal aims to develop a neuro-rare disease franchise, focusing on bexicaserin's potential to treat Developmental and Epileptic Encephalopathies (DEEs). Bexicaserin has shown significant seizure reduction in Phase 1b/2a studies and received breakthrough therapy designation from the FDA. Lundbeck plans to launch the drug in 2028 with peak sales potential of up to $2 billion.

Lundbeck to acquire Longboard Pharmaceuticals for $2.6bn, enhancing its neuro-rare conditions portfolio with bexicaserin, currently in Phase III clinical trials for developmental and epileptic encephalopathies.

Lundbeck to acquire Longboard Pharmaceuticals for $2.6 billion, gaining bexicaserin, an epilepsy drug in late-stage testing for developmental and epileptic encephalopathies (DEEs), with potential peak sales of $1.5-2.0 billion by 2028.

Lundbeck to acquire Longboard Pharmaceuticals for $2.6 billion, gaining access to its novel epilepsy drug, bexicaserin, which targets 5-HT2C receptors and has FDA breakthrough therapy designation. The deal, Lundbeck's largest, aims to address unmet needs in rare and severe epilepsies, with bexicaserin expected to launch by 2028 with potential sales of $1.5-$2 billion.

Lundbeck acquires Longboard Pharmaceuticals for DKK 17bn (USD 2.5bn), with CEO Charl van Zyl deeming the price reasonable.